Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Obeticholic Acid (OCA), a potent FXR agonist, is not approved for the treatment of Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn's disease (CD) (1, 2). In Inflammatory Bowel Disease (IBD), Obeticholic Acid (OCA) has been studied in animal colitis models, showing reduction in gut inflammation, improved barrier function, and modulation of immune signaling (1, 3). No published phase II/III clinical trials support OCA’s efficacy or approval for IBD, a…